OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	754
Tocilizumab in patients with severe COVID-19: a retrospective cohort study	683
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia	545
Anakinra for severe forms of COVID-19: a cohort study	489
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study	226
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study	216
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study	202
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study	190
Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome	184
The immunology of COVID-19: is immune modulation an option for treatment?	179
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine	173
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study	169
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study	163
Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries	143
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial	142
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial	128
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study	127
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study	125
COVID-19 vasculitis and novel vasculitis mimics	121
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies	116
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout	116
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	114
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study	113
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment	112
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study	105

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial	103
COVACTA trial raises questions about tocilizumab's benefit in COVID-19	101
Canakinumab in a subgroup of patients with COVID-19	98
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021	98
COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study	97
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study	94
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases	92
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative	89
Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study	87
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study	86
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?	79
Preventing COVID-19-induced pneumonia with anticytokine therapy	76
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses	74
Viral arthritis and COVID-19	70
Perspective of patients with autoimmune diseases on COVID-19 vaccination	70
Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study	69
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study	68
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study	68
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study	66
Too long to wait: the impact of COVID-19 on elective surgery	65
Flare of rheumatoid arthritis after COVID-19 vaccination	62
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study	61
First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection	60
Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study	59
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?	59
Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial	59
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study	56
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform	54
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study	54
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19	54